Genzyme Corp.’s Synvisc drug, a treatment for pain caused by osteoarthritis of the knee, will maintain a separate reimbursement code and rate for 2007, effectively reversing a decision made by the ...
Cambridge-based Genzyme Corp. said its Synvisc-One drug has been granted approval in Europe as a single-treatment pain management for knee osteoarthritis. The company said the approval is based on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results